Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CPBIO Holding CoHKSE:03839 -0.05%71 Quick Ratio is 1.39 as of Dec. 2025, which is 10% below its 10-year median of 1.55. GuruFocus rates HKSE:03839 with a GF Score™ of 71/100 and a GF Value™ of HK$4.36 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 999 Drug Manufacturers companies, CPBIO Holding Co ranks worse than 53.55% on this metric.
CPBIO Holding Co (HKSE:03839) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
CPBIO Holding Co Quick Ratio Related Terms
CPBIO Holding Co Quick Ratio Historical Data
* Premium members only.
The historical data trend for CPBIO Holding Co's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CPBIO Holding Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CPBIO Holding Co Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CPBIO Holding Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where CPBIO Holding Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
CPBIO Holding Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPBIO Holding Co (HKSE:03839) has a Quick Ratio of 1.39 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on CPBIO Holding Co and its competitors. This is 10% below median its historical median of 1.55. Over the past decade, CPBIO Holding Co's Quick Ratio has ranged from 1.08 to 3.66. According to the industry distribution chart, CPBIO Holding Co ranks #535 out of 999 companies in the Drug Manufacturers industry, placing it in the top 53.6%.
Is CPBIO Holding Co's Quick Ratio too high?
CPBIO Holding Co's current Quick Ratio of 1.39 is 10% below median its 10-year median of 1.55. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 3.66. The Drug Manufacturers industry median Quick Ratio is 1.44. CPBIO Holding Co's value of 1.39 is 3.5% below this industry median. Based on the distribution chart, CPBIO Holding Co ranks #535 out of 999 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, CPBIO Holding Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CPBIO Holding Co's Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CPBIO Holding Co ranks #535 out of 999 companies for Quick Ratio. This places CPBIO Holding Co in the lower half of its industry. The industry median Quick Ratio is 1.44. CPBIO Holding Co's value of 1.39 is 3.5% below this benchmark. Historically, CPBIO Holding Co's own Quick Ratio has ranged from 1.08 to 3.66 over the past decade. While the company's 10-year median is 1.55 vs. the industry median of 1.44, CPBIO Holding Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.44, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CPBIO Holding Co's current Quick Ratio of 1.39 is 3.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on CPBIO Holding Co and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CPBIO Holding Co's current Quick Ratio is 1.39, which is 10% below median its own 10-year median of 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CPBIO Holding Co stock overvalued right now?
Based on GuruFocus' analysis, CPBIO Holding Co (HKSE:03839) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$4.36, compared to a current price of HK$9.19 — trading 110.8% above its estimated fair value. The current Quick Ratio is 1.39, which is 10% below median its 10-year median of 1.55 and 3.5% below the Drug Manufacturers industry median of 1.44. CPBIO Holding Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For CPBIO Holding Co (HKSE:03839), the current Quick Ratio is 1.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CPBIO Holding Co (HKSE:03839) Overvalued in 2026?
Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued.
The current stock price of HK$9.19 is trading 110.8% above its estimated GF Value™ of HK$4.36.
GuruFocus considers CPBIO Holding Co to be Significantly Overvalued.
Key valuation signals for HKSE:03839:
Quick Ratio: 1.39 (10% below median its 10-year median of 1.55)
GF Value™: HK$4.36 vs. price of HK$9.19 (110.8% above fair value)
Industry Position: 3.5% below the Drug Manufacturers median (#535 of 999)
No single metric tells the full story. See the HKSE:03839 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
71GF Score
Get the complete analysis for HKSE:03839
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03839 has been successfully added to your 
